EcoDrugPlus

60s Ribosomal Protein L36a

Ensembl ID : ENSNGAG00000013440
Gene Symbol: LOC103746226
2 Cross references
84 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSNGAG00000001404
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSNGAG00000016571
Gene Symbol: ADAM17
3 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSNGAG00000020447
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSNGAG00000018674
Gene Symbol: AKT1
3 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSNGAG00000021194
Gene Symbol: AKT2
3 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSNGAG00000013336
Gene Symbol: AKT3
3 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSNGAG00000004733
Gene Symbol: ALK
3 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSNGAG00000012853
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSNGAG00000014435
Gene Symbol: ABCC8
3 Cross references
237 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSNGAG00000007570
Gene Symbol: ABCC9
2 Cross references
172 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSNGAG00000010161
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).